Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Department of Infectious Diseases, Rijnstate hospital, Arnhem, the Netherlands.
T J G
TJ
Gevers
D
D
Burger
E
E
Schipper-Reintjes
M P
MP
Kooistra
C
C
Richter
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002219:Carbamates; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines; D012367:RNA, Viral / Q000097:blood; D006435:Renal Dialysis; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000008:administration & dosage*; D000072230:Sustained Virologic Response; D014633:Valine / Q000031:analogs & derivatives; D019562:Viral Load
D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D012367:RNA, Viral; D012254:Ribavirin; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir